INmune Bio Inc (INMB)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $32.51M
Last updated: Nov 17, 2026 at 11:05 AM ET
INmune Bio Inc (INMB) Earnings: Report Dates and Results
INmune Bio (INMB) is expected to report earnings on Mar 29, 2027. In the quarter ended Sep 30, 2026, INmune Bio reported EPS of -$0.17, above the -$0.18 estimate. It beat the EPS estimate in 7 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
INMB has an expected report date of Mar 29, 2027.
INMB Earnings Call
The latest INMB earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 31 quarters below that had an estimate, INMB beat 19 and missed 12. The widest gap in the table came in the quarter ended Sep 30, 2020, when EPS landed 111.76% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.17 | -$0.18 | -$0.20 - -$0.17 | +5.56% | Beat | N/A | 2 | 1 up, 0 down | Nov 5, 2026 | N/A |
| Jun 30, 2026 | -$0.05 | -$0.20 | -$0.23 - -$0.17 | +75.00% | Beat | N/A | 2 | 1 up, 0 down | Aug 6, 2026 | N/A |
| Mar 31, 2026 | -$0.20 | -$0.18 | -$0.19 - -$0.17 | -11.11% | Miss | N/A | 2 | 1 up, 0 down | May 7, 2026 | N/A |
| Dec 31, 2025 | -$0.18 | -$0.27 | -$0.31 - -$0.24 | +33.33% | Beat | N/A | 3 | 2 up, 0 down | Mar 30, 2026 | N/A |
| Sep 30, 2025 | -$0.24 | -$0.32 | -$0.34 - -$0.31 | +25.00% | Beat | N/A | 2 | 1 up, 0 down | Oct 30, 2025 | N/A |
| Jun 30, 2025 | -$0.34 | -$0.37 | -$0.41 - -$0.37 | +8.11% | Beat | N/A | 5 | N/A | Aug 7, 2025 | N/A |
| Mar 31, 2025 | -$0.43 | -$0.45 | -$0.47 - -$0.43 | +4.44% | Beat | N/A | 4 | 3 up, 0 down | May 8, 2025 | $50000 |
| Dec 31, 2024 | -$0.40 | -$0.54 | -$0.58 - -$0.45 | +25.93% | Beat | N/A | 4 | 1 up, 2 down | Mar 27, 2025 | N/A |
| Sep 30, 2024 | -$0.60 | -$0.49 | -$0.55 - -$0.42 | -22.45% | Miss | N/A | 6 | 0 up, 0 down | Oct 31, 2024 | N/A |
| Jun 30, 2024 | -$0.50 | -$0.62 | -$0.65 - -$0.62 | +19.35% | Beat | N/A | 3 | 0 up, 0 down | Aug 1, 2024 | N/A |
| Mar 31, 2024 | -$0.61 | -$0.52 | -$0.55 - -$0.52 | -17.31% | Miss | N/A | 2 | 1 up, 0 down | May 9, 2024 | $14000 |
| Dec 31, 2023 | -$0.47 | -$0.44 | -$0.53 - -$0.35 | -6.82% | Miss | N/A | 2 | 0 up, 0 down | Mar 28, 2024 | $28000 |
| Sep 30, 2023 | -$0.48 | -$0.40 | -$0.42 - -$0.40 | -20.00% | Miss | N/A | 2 | 0 up, 0 down | Nov 1, 2023 | $43000 |
| Jun 30, 2023 | -$0.36 | -$0.38 | -$0.42 - -$0.37 | +5.26% | Beat | N/A | 3 | 0 up, 0 down | Aug 7, 2023 | $46000 |
| Mar 31, 2023 | -$0.36 | -$0.02 | -$0.02 - -$0.02 | N/A | N/A | N/A | 1 | 0 up, 0 down | May 3, 2023 | $38000 |
| Dec 31, 2022 | -$0.32 | -$0.48 | -$0.50 - -$0.47 | +33.33% | Beat | N/A | 2 | 0 up, 0 down | Mar 2, 2023 | $97000 |
| Sep 30, 2022 | -$0.43 | -$0.52 | -$0.59 - -$0.46 | +17.31% | Beat | N/A | 2 | 0 up, 0 down | Nov 2, 2022 | $98000 |
| Jun 30, 2022 | -$0.38 | -$0.47 | N/A | +19.15% | Beat | N/A | 2 | 0 up, 0 down | Aug 3, 2022 | $16000 |
| Mar 31, 2022 | -$0.39 | -$0.60 | -$0.60 - -$0.39 | +35.00% | Beat | N/A | 2 | 1 up, 0 down | May 5, 2022 | $163000 |
| Dec 31, 2021 | -$0.55 | -$0.58 | -$0.63 - -$0.54 | +5.17% | Beat | N/A | 3 | N/A | Mar 3, 2022 | $163000 |
| Sep 30, 2021 | -$0.55 | -$0.40 | -$0.43 - -$0.28 | -37.50% | Miss | N/A | 3 | 0 up, 0 down | Nov 3, 2021 | $14000 |
| Jun 30, 2021 | -$0.44 | -$0.34 | -$0.36 - -$0.32 | -29.41% | Miss | N/A | 4 | N/A | Aug 4, 2021 | N/A |
| Mar 31, 2021 | -$0.32 | -$0.28 | -$0.32 - -$0.23 | -14.29% | Miss | N/A | 3 | N/A | May 5, 2021 | $4000 |
| Dec 31, 2020 | -$0.26 | -$0.31 | -$0.38 - -$0.20 | +16.13% | Beat | N/A | 4 | N/A | Mar 4, 2021 | $11000 |
| Sep 30, 2020 | -$0.36 | -$0.17 | -$0.18 - -$0.16 | -111.76% | Miss | N/A | 3 | N/A | Nov 5, 2020 | N/A |
| Jun 30, 2020 | -$0.20 | -$0.23 | N/A | +13.04% | Beat | N/A | 2 | N/A | Aug 5, 2020 | N/A |
| Mar 31, 2020 | -$0.19 | -$0.21 | -$0.27 - -$0.14 | +9.52% | Beat | N/A | 3 | N/A | May 14, 2020 | N/A |
| Dec 31, 2019 | -$0.22 | -$0.25 | -$0.29 - -$0.18 | +12.00% | Beat | N/A | 3 | N/A | Mar 11, 2020 | $77.69M |
| Sep 30, 2019 | -$0.28 | -$0.19 | -$0.21 - -$0.18 | -47.37% | Miss | N/A | 3 | N/A | Nov 8, 2019 | N/A |
| Jun 30, 2019 | -$0.19 | -$0.20 | -$0.20 - -$0.18 | +5.00% | Beat | N/A | 2 | N/A | Aug 9, 2019 | N/A |
| Mar 31, 2019 | -$0.20 | -$0.19 | -$0.19 - -$0.19 | -5.26% | Miss | N/A | 1 | N/A | May 15, 2019 | N/A |
| Dec 31, 2018 | -$0.21 | -$0.19 | N/A | -10.53% | Miss | N/A | N/A | N/A | Mar 29, 2019 | N/A |
| Sep 30, 2018 | -$0.04 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 21, 2018 | N/A |
| Jun 30, 2018 | -$0.55 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 30, 2018 | N/A |
| Mar 31, 2018 | -$0.25 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 13, 2018 | N/A |
| Sep 30, 2017 | -$0.03 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 1, 2017 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.19, after -$2.11 the year before. It was -$1.08 for the year ended Dec 31, 2018, the oldest of the 8 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.19 | N/A |
| Dec 31, 2024 | -$2.11 | N/A |
| Dec 31, 2023 | -$1.67 | N/A |
| Dec 31, 2022 | -$1.52 | N/A |
| Dec 31, 2021 | -$1.86 | N/A |
| Dec 31, 2020 | -$1.01 | N/A |
| Dec 31, 2019 | -$0.89 | N/A |
| Dec 31, 2018 | -$1.08 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 3,700 words across 6 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 3,679 | 6 | |
| 2026Q2 | Jun 30, 2026 | 3,746 | 7 | |
| 2026Q1 | Mar 31, 2026 | 1,473 | 5 | |
| 2025Q4 | Dec 31, 2025 | 3,636 | 7 | |
| 2025Q3 | Sep 30, 2025 | 5,592 | 9 | |
| 2025Q2 | Jun 30, 2025 | 5,460 | 10 | |
| 2025Q1 | Mar 31, 2025 | 6,124 | 9 | |
| 2024Q3 | Sep 30, 2024 | 5,178 | 10 |
2026Q3 Earnings Call
Opening remarks
Daniel Frederick Carlson Head of Investor Relations Thank you, operator, and good afternoon, everyone. We thank you for joining us for INmune Bio's third-quarter 2026 financial results call. Presenting on today's call are David J. Moss, CEO and co-founder of INmune Bio; Dr. Mark Lowdell, chief scientific officer and co-founder of INmune Bio; and Cory Ellspermann, INmune Bio's CFO. Before we begin, I remind everyone that, except for statements of historical fact, the statements made by management and responses to questions on this conference call are forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that can cause actual results to differ materially from those expressed or implied by such forward-looking statements. Please see the forward-looking statements disclaimer in the company's earnings press release, as well as the risk factors in the company's SEC filings, including our most recent quarterly filings with the SEC. There is no assurance of any specific outcome. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made, as the facts and circumstances underlying these forward-looking statements may change. Except as required by law, INmune Bio disclaims any obligation to update these forward-looking statements to reflect future information, events, or circumstances. Now, it is my pleasure to turn the call over to INmune Bio's CEO, David J. Moss.
David J. Moss CEO and Co-Founder Thank you, Daniel, and good afternoon, everyone. Thank you for joining us for INmune Bio's third-quarter 2026 earnings call. This is an exciting time for INmune Bio. We are getting close to important milestones and entering a new phase in the company's development as we move Ebstracel toward regulatory approval and prepare to make it available to patients. During the quarter, we made important progress in manufacturing, regulatory preparation, and international patient expansion. Each of these steps brings us closer to our goal of transforming INmune Bio from a clinical-stage company into a commercial-stage company. The immediate focus is on execution, as we are getting very close. This involves assembling the complete regulatory package, establishing a practical route to patient access, and carefully allocating capital to these milestones. I want to be clear about our confidence in these activities. We believe the clinical data presents a compelling case for Ebstracel as a potentially first-in-class systemic treatment for RDEB. Importantly, Ebstracel addresses the top concerns of RDEB patients: itch, pain, inflammation, and wounds. Combined with the progress we have made in manufacturing and our discussions with regulators, we believe we are in a strong position as we move toward approval. Of course, the final decision rests with the regulatory agencies, but our confidence in the program remains very high.
Frequently Asked Questions About INMB
When is INmune Bio's next earnings date?
INmune Bio's next earnings report is expected for Mar 29, 2027.
Did INMB beat earnings estimates last quarter?
Yes. INmune Bio reported EPS of -$0.17 for the quarter ended Sep 30, 2026, above the -$0.18 estimate, a 5.56% surprise.
What EPS do analysts expect from INMB next quarter?
The consensus EPS estimate for INmune Bio for the quarter ending Dec 31, 2026 is -$0.20 from 6 analysts, with estimates from -$0.23 to -$0.15.
How often does INMB beat earnings estimates?
INmune Bio beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +20.78%.
INMB pages: Overview, Earnings, Forecast, Financials, Competitors